BioCentury
ARTICLE | Company News

Genzyme's Cerdelga gets CHMP nod for Gaucher's

November 22, 2014 2:24 AM UTC

EMA's CHMP recommended marketing authorization of Cerdelga eliglustat tartrate from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease.

Cerdelga is an oral ceramide analog that inhibits glucosylceramide synthase (GCS). ...